Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 7/20 | 0.77 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.77 |
| ▸ | CACNA1F | O60840 | 5/20 | 0.77 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.77 |
| ▸ | SCN1A | P35498 | 2/20 | 0.77 |
| ▸ | HTR2B | P41595 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.77 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.77 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.77 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29810716 | 1.00 | CACNA1C (0.77) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL7266381 | 0.95 | CACNA1B (0.74) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL8091424 | 0.95 | CACNA1C (0.70) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL5085498 | 0.95 | ADORA3 (0.86) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL7412221 | 0.95 | CACNA1B (0.74) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL11524993 | 0.93 | CACNA1C (0.67) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL11499593 | 0.92 | CACNA1C (0.66) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL9765770 | 0.92 | CACNA1C (0.86) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL6727785 | 0.91 | CACNA1D (0.72) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 | |
| SCHEMBL10823942 | 0.91 | CACNA1D (0.65) | CACNA1CCACNA1DCACNA1FCACNA1SADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| CN-114835633-B | Preparation method of nifedipine | 常州制药厂有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116425635-A | Method for synthesizing nifedipine intermediate by using combined catalyst | 合肥立方制药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-111233672-B | Method for synthesizing nifedipine intermediate by using combined catalyst | 合肥立方制药股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114835633-A | Preparation method of nifedipine | 常州制药厂有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-111233672-A | Method for synthesizing nifedipine intermediate by using combined catalyst | 合肥立方制药股份有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-1934561-B1 | IMPROVED TIME/TEMPERATURE INDICATORS | SUN CHEMICAL CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3288517-A1 | MEDICAL BATHING DEVICE | BSN Medical GmbH (DE) | 2018-03-07 | — | — | EP | disclosed |
| EP-3288893-A1 | MULTI-STEP PROCESS FOR NO PRODUCTION | BSN Medical Holding GmbH (DE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016174192-A1 | MEDICAL BATHING DEVICE | BSN MEDICAL GMBH (DE) | 2016-11-03 | — | — | WO | disclosed |
| US-4520131-A | WATER-SOLUBLE VASODIALATORS | USV PHARMACEUTICAL (US) | 1985-05-28 | — | — | US | disclosed |
| US-4505920-A | Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use | USV PHARMACEUTICAL CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| US-4500532-A | HYPOTENSIVE AGENTS | USV PHARMACEUTICAL CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| US-4497821-A | Medicaments having antihypoxic and ischaemia-protective activity | BAYER AKTIENGESELLSCHAFT (DE) | 1985-02-05 | — | — | US | disclosed |
| US-4491582-A | HYPOTENSIVE AGENTS | USV PHARMACEUTICAL CORPORATION (US) | 1985-01-01 | — | — | US | disclosed |
| EP-0124742-A2 | Process for the preparation of symmetric 1,4-dihydropyridine-carboxylic esters | BAYER AG (DE) | 1984-11-14 | — | — | EP | disclosed |
| EP-0124743-A2 | Process for the preparation of asymmetric 1,4-dihydropyridine-carboxylic acid esters | BAYER AG (DE) | 1984-11-14 | — | — | EP | disclosed |
| US-4478834-A | Dihydropyridines and their use in the treatment of asthma | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4472584-A | HYPOTENSIVE AGENTS | USV PHARMACEUTICAL CORPORATION (US) | 1984-09-18 | — | — | US | disclosed |
| US-4302591-A | 1-BENZIMIDOYL-DIHYDROPYRIDINES | USV PHARMACEUTICAL CORPORATION (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | CACNA1C 56/4885CACNA1D 77/4885CACNA1F 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.